XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs - Seite 2

XORTX has also initiated discussions with the US Medical Countermeasures Group associated with the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA) and separately with the National Institute of Health (NIH).  These communications with BARDA and NIH are expected to further aid development of XORTX’s XRx-101 program.

XORTX continues to seek non-dilutive funding for XRx-008 and XRx-101 programs with several granting agencies.

As previously stated in the Company’s prior press releases. The rationale for developing XRx-101 was made based on various in vivo studies showing that xanthine oxidase inhibition may confer suppression of viral infection and decrease symptoms of coronavirus COVID-19 infection and importantly improve survivability, and most importantly to protect the kidneys from AKI.

"The Company’s activities in the past month to advance both the XRx-008, for ADPKD and XRx-101 for acute kidney injury due to COVID-19 have accelerated as we focus on applications for non-dilutive funding opportunities for these programs. A number of discussions with granting agencies, regulatory agencies such as the FDA and partnership discussions are proceeding in an effort to help those individuals with kidney disease." said Dr. Allen Davidoff, CEO of XORTX Therapeutics Inc.

This news release contains forward-looking information relating to, among other things, statements with respect to the potential for XRx-101 as a treatment to suppress the severity of the coronavirus / COVID-19 infection. Although the Company believes that any such intentions, plans, estimates, beliefs and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs and expectations will prove to be accurate.

About FDA CTAP

FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.

https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treat ...

About BARDA

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing the U.S. from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA’s support includes funding, technical assistance and core services, ranging from a clinical research organization network to Centers for Innovation in Advanced Development and Manufacturing, and a fill-finish manufacturing network. To-date, BARDA has supported 42 FDA approvals for products addressing CBRN, PI, and EID threats.